Patients of childbearing potential unwilling to use contraceptive techniques
Fertile men or women unwilling to use contraceptives during and for up to 12 months following treatment
For fertile men and women, agreement to use effective contraceptive methods duration of study participation and 90 days after
Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
Fertile men or women who are unwilling to use contraceptives during HCT and up to 12 months post-treatment
Fertile men or women unwilling to use effective forms of birth control or abstinence for one year after transplantation
Fertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplant
Fertile patients unwilling to use contraception during and for 12 months after treatment
Unwilling to use approved contraception for at least 6 months following transplant
Fertile male and female patients must be willing to use an effective contraceptive method before, during, and for at least 4 months after the CAR T cell infusion
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
Women of childbearing potential and fertile men unwilling to use effective contraception during study until 4 months after conclusion of the treatment period
Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
Women of childbearing potential or fertile men unwilling to use effective contraception during study until conclusion of 4-week post-treatment evaluation period.
Fertile male and female patients must be willing to use a contraceptive method before, during, and for at least two months after the T cell infusion
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
INCLUSION CRITERIA FOR TNBC: Fertile male and female patients must be willing to use a contraceptive method before, during and for at least two months after the T cell infusion
Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
Fertile men should be willing to use barrier contraception during and for 4 months after AZD9291 (osimertinib), and fertile women must agree to use adequate contraceptive measures during and for 6 weeks after AZD9291 (osimertinib); fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.
Pregnant or lactating patients, or fertile female patients with a positive pregnancy test, or fertile female patients unwilling to use adequate contraception during treatment and for 30 days after completion of treatment
Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period.
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following transplant
Fertile men and women unwilling to use contraceptive techniques from the time of transplant until one month post maintenance therapy
Fertile men or women who are unwilling to use contraceptives during HCT and up to 12 months post-treatment
Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
Fertile men and women must agree to take adequate contraceptive precautions during, and for at least six months after therapy
Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
Fertile male patients willing to use adequate contraceptive measures
Fertile patients of child bearing age unwilling to use contraception during and for 12 months post-transplant
Fertile patients of either sex who do not use adequate contraceptive methods while on treatment
Fertile men or women unwilling to use contraceptive techniques from the time of initiation of mobilization until six-months post-transplant.
Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
Fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment, as well as females who are pregnant or actively breast feeding
Fertile males who are unwilling to use contraceptive techniques during and for the twelve months following treatment
Fertile men and women unwilling to use contraceptives during and for 12 months post-transplant
Patients unwilling to use contraceptive techniques before and for 12 months after HCT
Fertile men or women unwilling to use contraceptive techniques during and for 12 months following transplant
Fertile men or women unwilling to use contraception during HCT and for 12 months afterward